Zosano Pharma (NASDAQ:ZSAN) is up 20% premarket on increased volume. Shares have rallied over four-fold since February 23.
A week ago, the company was awarded a new U.S. patent protecting lead candidate M207.
Previously: Zosano Pharma issues new U.S. patent covering M207 as an acute treatment for migraine (March 2)
Subscribe for full text news in your inbox